升压药使用下自由皮瓣乳房重建结局:数据库驱动的倾向评分匹配分析
本研究利用TriNetX全国健康研究数据库,纳入2004至2024年间接受自由皮瓣乳房重建的乳腺癌患者,比较围手术期使用与未使用升压药两组经倾向评分匹配后的结局。匹配后每组6416例,升压药组主要结局(需微血管吻合修整、血管修复或皮瓣修整的皮瓣并发症)发生率显著更低(14.4% vs 16.0%,P=0.011),但主次要结局合计总并发症率无显著差异(16.6% vs 17.5%,P=0.084)。结论提示升压药在临床有指征时用于自体乳房重建人群是安全的。
要点
- 围手术期使用升压药未显著增加自由皮瓣乳房重建总并发症率。
- 升压药组皮瓣相关并发症率反而更低(14.4% vs 16.0%,P=0.011)。
- 临床有指征时使用升压药在自体乳房重建人群中被认为安全。
核心结论
- 围手术期使用升压药不影响自由皮瓣乳房重建的总并发症率。
- 使用升压药的患者皮瓣相关并发症率更低,但主次要结局合计无显著差异。
- 临床有指征时使用升压药在自体乳房重建人群中是安全的。
研究设计与样本
- 基于TriNetX LLC全国健康研究数据库的倾向评分匹配分析。
- 纳入2004至2024年间接受自由皮瓣重建的乳腺癌患者。
- 比较术后5天内使用与未使用升压药两组,匹配人口学与合并症后每组6416例。
主要发现
- 15548例中8392例使用升压药、7156例未使用,匹配后每组6416例。
- 主要结局率升压药组显著更低(14.4% vs 16.0%,P=0.011)。
- 次要结局率两组均很低(2.21% vs 1.48%,P=0.002)。
- 主次要结局合计总并发症率无显著差异(16.6% vs 17.5%,P=0.084)。
临床怎么用
- 临床有指征时可在自由皮瓣乳房重建围手术期使用升压药。
- 无需因担心皮瓣并发症而回避升压药的血流动力学管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous breast reconstruction with free tissue transfer is an integral component of treatment for breast cancer patients. Utilizing agents such as vasopressors for hemodynamic management during free flap surgery remains controversial, as vasoconstriction could decrease tissue perfusion and threaten the viability of the flap. However, the true effects of vasopressor use on microsurgical outcomes are unknown, and existing literature has found mixed results. Therefore, our study aims to analyze the outcomes of free-flap breast reconstruction in the setting of perioperative vasopressor use. METHODS: The TriNetX LLC National Health Research database was utilized to identify breast cancer patients who underwent free-flap reconstruction between 2004 and 2024. The database was further queried for those who did and did not receive vasopressors within 5 days of surgery, and the 2 cohorts were matched for their demographics and comorbidities. Diagnosis and current procedural terminology codes were then used to assess for flap complications within 7 days postoperatively. Primary outcomes included flap complications requiring revision of the microvascular anastomosis, vessel repair, and flap revision. Secondary outcomes included sepsis, venous thromboembolism, and hematoma evacuation. RESULTS: Of the 15,548 patients who underwent free-flap breast reconstruction, a total of 8,392 patients were associated with vasopressor use and 7,156 were not. When the two groups were matched, 6,416 patients were identified in each cohort. There was a significantly lower primary outcome rate in the group that received vasopressors (14.4% vs 16.0%; P = 0.011). Secondary outcome rates were very low in both groups (2.21% vs 1.48%; P = 0.002). When examining primary and secondary outcomes, there was no significant difference in total complication rate (16.6% vs 17.5%; P = 0.084). CONCLUSIONS: Our study demonstrates that perioperative vasopressor use does not significantly impact the complication rate associated with free-flap breast reconstruction. Interestingly, we found that patients who received vasopressors experienced a lower rate of flap-related complications. However, when analyzing all primary and secondary outcomes, there was no significant difference between the groups. These results suggest that vasopressor use is safe when clinically indicated in the autologous breast reconstruction population.
引用
- Julian O, Lee C, Newland M, et al. Outcomes of Free-Flap Breast Reconstruction With Vasopressor Use: A Database-Driven Propensity Score-Matched Analysis. Ann Plast Surg. 2026. PMID: 41687041. doi:10.1097/SAP.0000000000004688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。